FDA Accepts Review Of Takeda's Supplemental Biologics License Application For intravenous ENTYVIO
Benzinga Newsdesk 4 months ago
BiotechNewsFDAGeneral
If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's diseasePotential for ENTYVIO to address pediatric
- If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease
- Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda's commitment to advancing options where unmet treatment needs remain